Paper42638743
The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B.
Zhang Y and 4 others. Front Immunol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B. Papers, record 42638743. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42638743
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Immunologic | Major topic |
| Hepatitis B, Chronic | Major topic |
| Receptors, Tumor Necrosis Factor, Member 14 | Major topic |
| Hepatitis B virus | Major topic |
| Humans | |
| T-Cell Exhaustion | |
| Signal Transduction | |
| Animals | |
| Programmed Cell Death 1 Receptor |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30770415 | Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes. | J Immunol | 2019 | https://conductscience.org/library/papers/30770415 | PubMed |
| 2 | 38976867 | A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative. | Hepatology | 2025 | https://conductscience.org/library/papers/38976867 | PubMed |
| 3 | 40559604 | Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue. | Pathogens | 2025 | https://conductscience.org/library/papers/40559604 | PubMed |
| 4 | 40988451 | Current status of management of immune-related adverse events and practical needs for oncologist education. | Cancer Biol Med | 2025 | https://conductscience.org/library/papers/40988451 | PubMed |
| 5 | 33917094 | BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33917094 | PubMed |
| 6 | 31204070 | The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis. | Immunity | 2019 | https://conductscience.org/library/papers/31204070 | PubMed |
| 7 | 27793593 | Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells. | Immunity | 2016 | https://conductscience.org/library/papers/27793593 | PubMed |
| 8 | 32437509 | PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. | J Cell Biol | 2020 | https://conductscience.org/library/papers/32437509 | PubMed |
| 9 | 22658127 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658127 | PubMed |
| 10 | 30622109 | Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. | Gut | 2019 | https://conductscience.org/library/papers/30622109 | PubMed |
| 11 | 41179730 | Hepatitis B functional cure: Current and future perspective. | World J Hepatol | 2025 | https://conductscience.org/library/papers/41179730 | PubMed |
| 12 | 29853659 | Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. | Oncologist | 2018 | https://conductscience.org/library/papers/29853659 | PubMed |
| 13 | 33332777 | The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells. | Immun Inflamm Dis | 2021 | https://conductscience.org/library/papers/33332777 | PubMed |
| 14 | 20038811 | BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20038811 | PubMed |
| 15 | 30580250 | Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. | Gut | 2019 | https://conductscience.org/library/papers/30580250 | PubMed |
| 16 | 34734802 | Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors. | Elife | 2021 | https://conductscience.org/library/papers/34734802 | PubMed |
| 17 | 34172516 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34172516 | PubMed |
| 18 | 35312715 | Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis. | PLoS One | 2022 | https://conductscience.org/library/papers/35312715 | PubMed |
| 19 | 32206094 | Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. | Ther Adv Musculoskelet Dis | 2020 | https://conductscience.org/library/papers/32206094 | PubMed |
| 20 | 25101233 | Immunosuppression in Patients with Chronic Hepatitis B. | Curr Hepatol Rep | 2014 | https://conductscience.org/library/papers/25101233 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| BTLA | 151888 | PubTator's text mining | https://conductscience.org/library/genes/151888 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| NR0B2 | 8431 | PubTator's text mining | https://conductscience.org/library/genes/8431 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
| PTPN11 | 5781 | PubTator's text mining | https://conductscience.org/library/genes/5781 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
| TNFRSF14 | 8764 | PubTator's text mining | https://conductscience.org/library/genes/8764 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42638743
GET https://conductscience.org/api/papers/v1/42638743/references?page=2